相关实验视频

Updated: May 6, 2026

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Clinical Application of Sleeping Beauty and Artificial Antigen Presenting Cells to Genetically Modify T Cells from Peripheral and Umbilical Cord Blood

Published on: February 1, 2013

[在DLBCL和早期复发 (<12个月) 的老年患者中进行CAR-T细胞治疗

Enrico Orciuolo¹

¹UO Ematologia, Azienda Ospedaliero Universitaria Pisana.

Recenti progressi in medicina

|February 20, 2026

概括

艾克西卡巴丁基诺基 (axi-cell) 疗法对早期复发的老年扩散性大B细胞淋巴瘤 (DLBCL) 患者有前途. 这种病例显示了可管理的并发症和持续的积极结果超过10个月.

科学领域:

在瘤学瘤学.
血液学血液学血液学
免疫治疗是一种免疫疗法.

背景情况:

扩散性大B细胞淋巴瘤 (DLBCL) 是一种侵略性的非霍奇金淋巴瘤.
在一线治疗后的早期复发在DLBCL管理中构成了重大挑战.
老年患者通常对治疗耐受性和疗效有特殊考虑.

研究的目的:

报告一个成功的治疗案例的轴细胞疗法在一个老年DLBCL患者与早期复发.
在这个患者群体中评估轴细胞治疗的安全性和耐受性.
评估轴细胞输液后的临床结果和响应的持续时间.

主要方法:

一位患有复发DLBCL的老年患者接受了轴细胞疗法.
在住院期间和输液后进行并发症的临床监测.
长期跟踪评估疾病状态和不良事件.

主要成果:

患者在初始治疗后经历了DLBCL的早期复发.
进行了axi细胞疗法,并观察到并发症.
观察到的并发症是可以管理的,不需要密集干预.
患者在输液后的10个月内保持了无危急状态.

结论:

对早期复发的老年DLBCL患者来说,细胞疗法可以是一个可行的和有效的治疗选择.
在选择的老年患者中,轴细胞的安全性似乎是可以控制的.
在此案例研究中观察到持续的临床益处和可控的毒性.

更多相关视频

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Dynamic Imaging of Chimeric Antigen Receptor T Cells with [18F]Tetrafluoroborate Positron Emission Tomography/Computed Tomography

Published on: February 17, 2022

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy

Published on: February 21, 2025

相关概念视频

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...